Can a migraine drug stop Post-Concussion headaches?

NCT ID NCT04098250

Completed Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small study tested whether the drug erenumab (Aimovig) can prevent persistent headaches after a mild traumatic brain injury. Six adults with recent post-traumatic headache were given either erenumab or a placebo. The goal was to see if the drug could reduce the number of moderate-to-severe headache days over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Erenumab (Aimovig)
What this could lead to: If it works, this could point toward a treatment to prevent post-traumatic headaches from becoming chronic after a mild brain injury.
What could go wrong: This is a very small, early-phase trial with only 6 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST TRAUMATIC HEADACHE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Headache Post-Traumatic Headache

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POST TRAUMATIC HEADACHE

Contacts and locations

Locations

Mayo Clinic

Phoenix, Arizona, 85054, United States
Mayo Clinic

Jacksonville, Florida, 32224, United States
Mayo Clinic

Rochester, Minnesota, 55901, United States
Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Phoenix VA Health Care System

Phoenix, Arizona, 85012, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.